Apollo Hospitals Q1 Results FY26: Q1 PAT Rises 41.81% to ₹432.80 Crore; Revenue Up 14.81% YoY

Apollo Hospitals Q1 Results FY26: Extracts of FY25 & FY26 (Consolidated Figures)

(Figures in crores)

Apollo Hospitals Q1 Results FY26: Extracts of FY25 & FY26 (Standalone Figures)

(Figures in crores)

Apollo Hospitals Q1 Results FY26 Highlights (Q1 FY26 vs FY25)

• Apollo Hospitals clocked Q1 FY26 consolidated revenue of ₹5,842.10 crores vs ₹5,085.60 crores. 
• On the profit front, Apollo Hospitals earned a consolidated PAT of ₹432.80 crore in Q1 FY26. During FY25, the company’s PAT stood at ₹305.20 crore. 
• Consolidated PAT rose for the first quarter of FY26, was 41.81% YoY, and revenue rose 14.88% YoY. 
• As per the standalone figures, the quarterly PAT of Apollo Hospitals has increased by 21.93%, and revenue has increased by 11.94% YoY.

Apollo Hospitals Share Price Performance

On the opening bell of 13th August 2025, the shares of Apollo Hospitals opened at ₹7,406.00 per share. However, the initial gains are sustained as of now, and Apollo Hospitals shares are trading at ₹7,740.00 per share, higher than their opening price. 

Considering the long-term performance, Apollo Hospitals shares have yielded close to -24.06% returns in the past 1 year, and 5-year returns stand at 890.30%. Over the maximum timeframe, the Apollo Hospitals share provided 34.66% returns to investors. However, one must ignore the risk of volatility in the stock market and invest in Apollo Hospitals shares after thorough research. 

For regular stock updates, dividend alerts, and expert verdicts, stay informed with Univest!

Disclaimer: Investment in the share market is subject to risk. This news article is for informational purposes only. Conduct your own research before investing in shares and other securities.

Recent Articles

Finolex Cables Q1 Results FY26: Q1 PAT Falls 33.33% to ₹162.62 Crore; Revenue Up 13.41% YoY

Abbott India Q1 Results FY26: Q1 PAT Rises 11.54% to ₹365.86 Crore; Revenue Up 11.60% YoY

Jyothy Labs Q1 Results FY26: Q1 PAT Falls 4.95% to ₹96.73 Crore; Revenue Up 1.35% YoY

Zydus Lifesciences Q1 Results FY26: Q1 PAT Rises 3.30% to ₹1,466.80 Crore; Revenue Up 5.90% YoY

Bombay Burmah Trading Q1 Results FY26: Q1 PAT Soars 8.28% to ₹240.70 Crore; Revenue Up 8.73% YoY

Alkem Laboratories Q1 Results FY26: Q1 PAT Rises 21.85% to ₹664.26 Crore; Revenue Up 11.19% YoY

Natco Pharma Q1 Results FY26: Q1 PAT Falls 28.09% to ₹480.70 Crore; Revenue Down 2.47% YoY